An Assessment of the Prevalence of Psoriasis in Patients with Hepatitis C

An Assessment of the Prevalence of Psoriasis in Patients with Hepatitis C - An Assessment of the Prevalence of Psoriasis in Patients with Hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34745

Enrollment

Registered

2010-05-19

Start date

2010-03-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic skin disease with increased keratinization psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Age 18 years or greater 2.Subjects must have a previous diagnosis of Hepatitis C. This would include all patients with a positive serology for Hepatitis C. 3.Patients in the treatment group should be treated for at least one dose, within the last 6 months, with pegylated interferon-*.

Exclusion criteria

Exclusion criteria: 1.Subjects younger than 18 years old 2.Subjects with any skin disease, disease state, or physical condition that would impair evaluation of the skin, for example not able to undress or stand up.

Design outcomes

Primary

Measure	Time frame
Efficacy outcome measurement will include evaluation of the skin for either the presence or absence of psoriasis, through the psoriasis area severity index (PASI) . Additionally, patients will be evaluated for total Body Surface Area (BSA) involved. An average palm represents 1% of the BSA.	—

Countries

Netherlands

Outcome results